Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508501 | 1.00 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL674905 | 0.91 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL4506565 | 0.91 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL4497043 | 0.89 | CNR1 (0.77) | CNR1CNR2 | |
| SCHEMBL4510012 | 0.89 | CNR1 (0.77) | CNR1CNR2 | |
| SCHEMBL6104725 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6104428 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6879980 | 0.87 | CNR1 (0.73) | CNR1CNR2 | |
| SCHEMBL4511060 | 0.86 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL675659 | 0.86 | CNR1 (1.00) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | claimed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | claimed |
| US-11059779-B2 | Storage stable aqueous organic peroxide emulsions | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2021-07-13 | — | — | US | disclosed |
| EP-3429991-B1 | STORAGE STABLE AQUEOUS ORGANIC PEROXIDE EMULSIONS | NOURYON CHEMICALS INT BV (NL) | 2020-05-06 | — | — | EP | disclosed |
| US-20190071397-A1 | STORAGE STABLE AQUEOUS ORGANIC PEROXIDE EMULSIONS | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2019-03-07 | — | — | US | disclosed |
| EP-1373198-B2 | STORAGE STABLE AQUEOUS ORGANIC PEROXIDE EMULSIONS | AKZO NOBEL NV (NL) | 2015-02-25 | — | — | EP | disclosed |
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. | 2009-07-16 | — | — | US | disclosed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | disclosed |
| EP-1373198-B1 | STORAGE STABLE AQUEOUS ORGANIC PEROXIDE EMULSIONS | AKZO NOBEL NV (NL) | 2008-04-23 | — | — | EP | disclosed |
| US-7214329-B2 | For use in polymerization of vinyl chloride monomer | AKZO NOBEL N.V. (NL) | 2007-05-08 | — | — | US | disclosed |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
| EP-1438296-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-07-21 | — | — | EP | disclosed |
| US-20040132938-A1 | For use in polymerization of vinyl chloride monomer | WILMINGTON TRUST (LONDON) LIMITED, AS COLLATERAL AGENT (GB) | 2004-07-08 | — | — | US | disclosed |
| WO-2003027076-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | CNR1, CNR2, CHRM1 | CNR1 1/4885CNR2 2/4885 |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | CNR1, CNR2, CHRM1 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.